EA006556B1 - Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот - Google Patents

Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот Download PDF

Info

Publication number
EA006556B1
EA006556B1 EA200301057A EA200301057A EA006556B1 EA 006556 B1 EA006556 B1 EA 006556B1 EA 200301057 A EA200301057 A EA 200301057A EA 200301057 A EA200301057 A EA 200301057A EA 006556 B1 EA006556 B1 EA 006556B1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty acid
group
compounds
compound
alkyl
Prior art date
Application number
EA200301057A
Other languages
English (en)
Russian (ru)
Other versions
EA200301057A1 (ru
Inventor
Даниелли Пиомелли
Фернандо Родригес Де Фонсека
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA200301057A1 publication Critical patent/EA200301057A1/ru
Publication of EA006556B1 publication Critical patent/EA006556B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EA200301057A 2001-03-27 2002-03-27 Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот EA006556B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27954201P 2001-03-27 2001-03-27
US33628901P 2001-10-31 2001-10-31
PCT/US2002/009773 WO2002080860A2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Publications (2)

Publication Number Publication Date
EA200301057A1 EA200301057A1 (ru) 2004-04-29
EA006556B1 true EA006556B1 (ru) 2006-02-24

Family

ID=26959730

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301057A EA006556B1 (ru) 2001-03-27 2002-03-27 Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот

Country Status (11)

Country Link
US (3) US6911474B2 (enExample)
EP (1) EP1408945A4 (enExample)
JP (1) JP2004526745A (enExample)
KR (1) KR20030087657A (enExample)
CN (1) CN1523982A (enExample)
AU (1) AU2002338329B2 (enExample)
CA (1) CA2442683A1 (enExample)
EA (1) EA006556B1 (enExample)
IL (1) IL158131A0 (enExample)
MX (1) MXPA03008823A (enExample)
WO (1) WO2002080860A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096429A3 (en) * 2011-12-19 2013-08-15 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
US8829050B2 (en) 2006-03-23 2014-09-09 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US9040584B2 (en) 2013-05-10 2015-05-26 Topokine Therapeutics, Inc. Compositions for topical delivery of prostaglandins to subcutaneous fat
US9089579B2 (en) 2011-01-19 2015-07-28 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006556B1 (ru) 2001-03-27 2006-02-24 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
CA2475630C (en) 2002-02-12 2011-01-18 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
US20040157932A1 (en) * 2002-11-18 2004-08-12 Natural Asa, Supplements and foods comprising oleylethanolamide
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
EP1677780A4 (en) * 2003-10-16 2007-05-02 Univ California DIETARY AND OTHER FOODS, COMPOUNDS AND METHOD FOR REDUCING BODY FAT, APPETIZING AND MODULATING THE FATTY ACID CHANGES
EP1570752B1 (en) * 2004-03-06 2008-07-02 Cognis IP Management GmbH Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme
JP2006061086A (ja) * 2004-08-27 2006-03-09 Morishita Jintan Kk 脂肪代謝改善効果を有する被験試料のスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007006319A2 (en) * 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
DE602007010420D1 (de) 2006-04-11 2010-12-23 Arena Pharm Inc Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US20090208513A1 (en) * 2007-09-07 2009-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
EP2146210A1 (en) * 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
BRPI0912774A2 (pt) * 2008-05-19 2017-05-23 Nestec Sa métodos para reduzir absorção de lipídio por um animal
CN102791145A (zh) * 2010-03-24 2012-11-21 雀巢产品技术援助有限公司 增强可食用组合物的适口性的方法
US9511042B2 (en) 2010-07-02 2016-12-06 Helix Biomedix Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
CA2835429A1 (en) * 2011-05-10 2012-11-15 Nestec S.A. Methods and compositions for promoting lean body mass growth
AU2012253701A1 (en) * 2011-05-10 2013-11-21 Nestec S.A. Methods and compositions for preserving lean body mass during weight loss
CN102579414A (zh) * 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
WO2013160492A1 (es) * 2012-04-24 2013-10-31 Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) Terapia combinada para el tratamiento de enfermedades metabólicas
US9221747B2 (en) 2012-04-25 2015-12-29 Iowa State University Research Foundation, Inc. Method of making fatty acid N-acylalkanolamines
CN102675141A (zh) * 2012-05-04 2012-09-19 庄信修 N-(2-羟基乙基)芥酰胺及其制备与用途
WO2014037546A1 (en) 2012-09-07 2014-03-13 Nestec S.A. Oleoylethanolamide compositions
CN102824338A (zh) * 2012-09-18 2012-12-19 厦门大学 s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途
CN103113253A (zh) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
PH12018000227A1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1274783B (it) * 1994-12-15 1997-07-24 Antonio Picarelli Preparato per il trattamento dell'obesita'
CA2215387A1 (en) * 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
ES2217392T3 (es) 1996-02-02 2004-11-01 MERCK & CO., INC. Agentes antidiabeticos.
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5803916A (en) 1996-03-19 1998-09-08 Vital-Tech Ltd. Body and joints massage device
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6974568B2 (en) 2000-05-23 2005-12-13 The Regents Of The University Of California Treatment for cough
EA006556B1 (ru) 2001-03-27 2006-02-24 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
JP5093967B2 (ja) * 2001-04-06 2012-12-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
CA2455555A1 (en) * 2001-07-31 2003-02-13 The Scripps Research Institute Animal model for fatty acid amide-related neurobehaviors
EP1472215A4 (en) 2002-02-08 2007-05-09 Bristol Myers Squibb Co (OXIME) CARBAMOYL, FATTY ACID AMIDE HYDROLASE INHIBITORS
US20040157932A1 (en) 2002-11-18 2004-08-12 Natural Asa, Supplements and foods comprising oleylethanolamide

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421215B2 (en) 2006-03-23 2016-08-23 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US10285995B2 (en) 2006-03-23 2019-05-14 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US8829050B2 (en) 2006-03-23 2014-09-09 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US8877807B2 (en) 2006-03-23 2014-11-04 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US9795614B2 (en) 2006-03-23 2017-10-24 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US9144574B2 (en) 2006-03-23 2015-09-29 Topokine Therapeutics, Inc. Compositions and methods for reducing body fat
US10335418B2 (en) 2011-01-19 2019-07-02 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
US9504695B2 (en) 2011-01-19 2016-11-29 Topokine Therapeutics, Inc. Methods for reducing body fat
US9089579B2 (en) 2011-01-19 2015-07-28 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
US9861641B2 (en) 2011-12-19 2018-01-09 Topokine Therapeutics, Inc. Methods for reducing body fat using tafluprost and analogs thereof
US9180130B2 (en) 2011-12-19 2015-11-10 Topokine Therapeutics, Inc. Tafluprost and analogs thereof for reducing fat
WO2013096429A3 (en) * 2011-12-19 2013-08-15 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US8569376B2 (en) 2011-12-19 2013-10-29 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US8883834B2 (en) 2012-11-21 2014-11-11 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
US9040584B2 (en) 2013-05-10 2015-05-26 Topokine Therapeutics, Inc. Compositions for topical delivery of prostaglandins to subcutaneous fat
US9849179B2 (en) 2013-05-10 2017-12-26 Topokine Therapeutics, Inc. Methods for topical delivery of prostaglandins to subcutaneous fat
US10556012B2 (en) 2013-05-10 2020-02-11 Topokine Therapeutics, Inc. Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10869874B2 (en) 2013-05-15 2020-12-22 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen

Also Published As

Publication number Publication date
US7423066B2 (en) 2008-09-09
EP1408945A4 (en) 2005-07-06
KR20030087657A (ko) 2003-11-14
IL158131A0 (en) 2004-03-28
JP2004526745A (ja) 2004-09-02
US20030018081A1 (en) 2003-01-23
US6911474B2 (en) 2005-06-28
AU2002338329B2 (en) 2006-09-07
MXPA03008823A (es) 2004-08-12
CA2442683A1 (en) 2002-10-17
US20090005447A1 (en) 2009-01-01
WO2002080860A3 (en) 2004-02-26
CN1523982A (zh) 2004-08-25
WO2002080860A2 (en) 2002-10-17
AU2002338329C1 (en) 2002-10-21
EA200301057A1 (ru) 2004-04-29
EP1408945A2 (en) 2004-04-21
US20050187254A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
EA006556B1 (ru) Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
AU2002338329A1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
Grant et al. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges
Alwan et al. Onco-immunity and therapeutic application of amygdalin: A review
MXPA04011333A (es) Uso de compuestos que son efectivos como moduladores selectivos de receptores opiaceos.
CA2542547A1 (en) Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
Kim et al. Central administration of metformin into the third ventricle of C57BL/6 mice decreases meal size and number and activates hypothalamic S6 kinase
KR20180103027A (ko) 신경발달장애 예방, 개선 또는 치료용 엘-세린 조성물
KR20180037597A (ko) 시계 유전자의 발현을 변화시키기 위한 조성물
KR101213570B1 (ko) 우울증을 치료 또는 예방하기 위하여 사용되는 약제 또는 기능성 식품의 제조에 사용되는 5?메틸?1，3?벤젠디올 또는 그의 유도체의 용도
JP5354741B2 (ja) 睡眠改善剤
BRPI0706865A2 (pt) método para preparar extrato de shinyleaf yellowhorn e extrato de shinyleaf yellowhorn
AU2024228270A1 (en) Traditional chinese medicine composition for treating amyotrophic lateral sclerosis and use thereof
JP5557243B2 (ja) 睡眠の改善剤
WO2019228994A1 (en) Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses
JP2009516637A (ja) 消化管機能亢進剤
KR101737051B1 (ko) 당뇨병 치료용 약학적 조성물
CN112691089B (zh) 1-苯基-1-丙醇在制备治疗高血脂和/或糖尿病药物中的应用
JP2004215562A (ja) 飲食物用添加剤、医薬組成物、ｇｌｕｔ４トランスロケート剤及びトランスロケート方法
TW202535421A (zh) 用於提高生物能量代謝之含有蔗果三糖的組成物
JP6570052B2 (ja) 概日リズム改善剤
Hofer The effect of reduced levels of NSM 2 in the brain on food reward learning in fro mice
CN106806365A (zh) 补骨脂素在制备治疗高脂血症药物中的用途
KR20130091604A (ko) 시난디온 ａ를 포함하는 항염증용 조성물
UA77627C2 (en) Method (variants) and composition (variants) for reducing body weight and modulating body lipid metabolism in mammals

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ MD RU